Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +48 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607601 |
| 2 | ▲3 | Malignant Bladder Neoplasm | +24 | 96 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607603 |
| 2 | ▲2 | Malignant Laryngeal Neoplasm | +24 | 96 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607602 |
| 4 | ▼1 | Cutaneous Melanoma | +20 | 88 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607604 |
| 5 | ▲4 | Malignant Esophageal Neoplasm | +16 | 84 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607605 |
| 5 | ▲10 | Malignant Pancreatic Neoplasm | +16 | 84 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607606 |
| 5 | ▲3 | Malignant Salivary Gland Neoplasm | +16 | 84 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607607 |
| 8 | ▲9 | Malignant Prostate Neoplasm | +12 | 72 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607608 |
| 8 | ▼1 | Malignant Testicular Neoplasm | +12 | 72 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607609 |
| 10 | ▲2 | Malignant Mesothelioma | +8 | 64 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607610 |
| 11 | ▲5 | Malignant Kidney Neoplasm | +4 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607611 |
| 11 | ▲11 | Malignant Liver Neoplasm | +4 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607612 |
| 11 | ▲3 | Malignant Rectal Neoplasm | +4 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607613 |
| 14 | ▲6 | Malignant Anal Neoplasm | 0 | 48 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607616 |
| 14 | ▲9 | Malignant Lung Neoplasm | 0 | 48 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607614 |
| 14 | ▲10 | Malignant Thyroid Gland Neoplasm | 0 | 48 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607615 |
| 17 | ▲3 | Malignant Hypopharyngeal Neoplasm | -4 | 36 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607617 |
| 17 | ▲2 | Malignant Penile Neoplasm | -4 | 36 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607618 |
| 19 | ▲7 | Leukemia | -8 | 28 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607619 |
| 19 | ▲7 | Malignant Central Nervous System Neoplasm | -8 | 28 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607620 |
| 21 | ▲9 | Hodgkin Lymphoma | -12 | 20 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607621 |
| 22 | ▲6 | Malignant Gastric Neoplasm | -16 | 16 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607622 |
| 22 | ▲7 | Multiple Myeloma | -16 | 16 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607623 |
| 24 | ▲7 | Non-Hodgkin Lymphoma | -24 | 8 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607624 |
| 25 | ▲7 | Malignant Nasopharyngeal Neoplasm | -32 | 4 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607625 |
| 26 | ▲10 | Malignant Breast Neoplasm | -88 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2607626 |
Data updated 16 hours agoSource updated unknown26 eligible entities · inputs hash 922c8783f8783cba4f334ad8